Matrix metalloproteinases in destructive pulmonary pathology

P T G Elkington, J S Friedland

Matrix metalloproteinases (MMPs) are a family of proteolytic enzymes that have a number of important physiological roles including remodelling of the extracellular matrix, facilitating cell migration, cleaving cytokines, and activating defensins. However, excess MMP activity may lead to tissue destruction. The biology of MMP and the role of these proteases in normal pulmonary immunity are reviewed, and evidence that implicates excess MMP activity in causing matrix breakdown in chronic obstructive pulmonary disease (COPD), acute respiratory distress syndrome (ARDS), sarcoidosis, and tuberculosis is discussed. Evidence from both clinical studies and animal models showing that stromal and inflammatory cell MMP expression leads to immunopathology is examined, and the mechanisms by which excess MMP activity may be targeted to improve clinical outcomes are discussed.

Normal lung function requires alveolar support by the extracellular matrix (ECM). In many pulmonary diseases abnormal remodelling or destruction of the ECM occurs, leading to impaired lung function and, if extensive, death. Consideration of the biochemistry of the lung matrix predicts that the matrix metalloproteinase (MMP) family of enzymes is likely to be involved in this pathology. MMPs are proteases that collectively can degrade all components of the ECM, but also have important roles in normal immunity. Thus, MMPs may modulate appropriate responses to exogenous stimuli but may also contribute to immunopathology that leads to aberrant turnover of the ECM. We review the roles of MMPs in normal pulmonary immunity and discuss four diseases where excess MMP activity may contribute to pulmonary destruction: chronic obstructive pulmonary disease (COPD), the acute respiratory distress syndrome (ARDS), sarcoidosis, and tuberculosis (TB).

THE PULMONARY ECM

The pulmonary interstitium forms the mechanical scaffold of the lung, while the basement membrane supports alveolar epithelial cells and in part determines the resistance of the diffusion barrier. The primary structural fibrils of the lung are type I collagen which provides tensile strength, and elastin which allows distensibility. Elastin fibres are usually highly stable and often last life-long. The alveolar wall is primarily made from type III collagen while the basement membrane is rich in type IV collagen. Large collagen and elastin fibres are connected by a variety of smaller fibrils. Degradation of the primary structural fibrils of the lung will therefore first involve cleavage of the cross linking fibrils to expose enzyme binding sites. Consequently, multiple enzymes are likely to be involved in the turnover of the ECM, and it may be impossible to specify a single protease as the critical mediator of any particular pulmonary pathology. MMP involvement in degradation of the lung ECM is predicted since fibrillar type I collagen is highly resistant to enzymatic degradation and only certain MMPs can degrade it at neutral pH. Furthermore, multiple MMPs are elastases and MMPs also degrade type IV collagen.

MATRIX METALLOPROTEASES

MMPs are a family of zinc dependent proteases that were initially identified in the involution tail of tadpoles by their ability to degrade collagen. MMPs can be broadly classified on the basis of substrate specificity into collagenases (MMP-1, -8 and -13), gelatinases (MMP-2 and -9), stromelysins (MMP-3, -10, -11), elastases (MMP-7 and -12), and membrane type MMPs (MT-MMPs, MMP-14, -15, -16 and -17) which are surface anchored. MMP-1 (interstitial collagenase), MMP-8 (neutrophil collagenase), MMP-13 (collagenase 3), and MMP-14 (MT1-MMP) can cleave the triple helix of native type I collagen, the primary architectural collagen of the lung. Elastolytic MMPs include MMP-2 (gelatinase A), MMP-7 (matrilysin), MMP-9 (gelatinase B), and MMP-12 (macrophage metalloelastase).

Since MMPs may cause significant host damage, they are tightly regulated. Firstly, they are rarely stored but require gene transcription before secretion, the exception being neutrophil MMP-8 and -9. Secondly, they are either secreted as pro-enzymes that require proteolytic cleavage or, in the case of MT-MMPs, activated intracellularly by pro-protein convertases such as furin. This processing exposes the catalytic cleft, a mechanism known as the cysteine switch. Thirdly, specific inhibitors of MMPs—the tissue inhibitors of metalloproteinases (TIMPs)—are...
secretion is primarily regulated by the prostaglandin (PG) model. MMP activity is therefore required for both stromal repair. This hypothesis is supported by the observation that MMP-7 knock-out mice have deficient epithelial cell migration. MMP-7 activity is required to cleave syndecan-1 on pulmonary epithelial cells, thereby releasing and activating KC, permitting KC to exert its biological activity and thus drive neutrophil influx.

In addition to modulating the activity of cytokines and chemokines, MMPs can mediate intercellular signalling directly. MMP-1 can cleave proteinase activated receptor 1 (PAR-1) on the cell surface, initiating a G-protein dependent intracellular signalling cascade and calcium flux. In a model of malignant invasion, activation of PAR-1 by MMP-1 led to increased tumour invasiveness. MMP-1 was derived from fibroblasts, not malignant cells, which shows that MMPs may modulate interactions between invading and stromal cells.

**Defensin activation**

In the gut MMP-7 activates the antimicrobial peptides pro-α-defensins and may play a similar role in the lung. The functional importance of α-defensin activation is shown by the delayed clearance of bacteria from the bowel in MMP-7 deficient mice. MMP-7 expression in airway epithelial cells is upregulated in diseases characterised by chronic infection such as cystic fibrosis, supporting the hypothesis that MMP-7 contributes to pulmonary immunity. Furthermore, bacterial components alone can actively drive MMP-7 secretion from cultured pulmonary epithelial cells. Together with the release of anchored chemokines by MMP-7, these results have led to the hypothesis that MMP-7 secretion may be part of a generalised activation response to bacteria.

The data outlined above indicate that MMPs play important roles in normal pulmonary immunity by facilitating cell migration, modulating chemokine and cytokine activity, activating defensins, and mediating intercellular signalling. However, extensive evidence has accumulated that altered MMP activity can lead to disease. The number of pulmonary conditions in which MMPs have been implicated in the pathology encompasses much of thoracic medicine (table 1) and so cannot be addressed within a single review. Here, we examine four conditions—COPD, ARDS, sarcoidosis, and TB—where destruction of the pulmonary ECM is a
key component of the disease process, and review evidence that excessive MMP activity contributes to this pathology.

**CHRONIC OBSTRUCTIVE PULMONARY DISEASE**

The observation that smokers with $\alpha_{1}$-antitrypsin deficiency develop COPD provided the initial indication that a protease/antiprotease imbalance can drive pulmonary pathology. Since neutrophil elastase is one of the enzymes inhibited by $\alpha_{1}$-antitrypsin, excess elastase activity was initially thought to be responsible for the destructive pathology in COPD. However, although there is considerable evidence for the involvement of neutrophil elastase in COPD, it now seems that multiple proteases acting in concert cause pulmonary destruction. The turnover of the lung ECM will involve the interaction of several enzymes as cross linking fibrils must first be cleaved to expose the major fibres to allow their degradation. Since MMPs degrade all components of the ECM including type I collagen and elastin, they are likely to be involved in tissue remodelling in COPD.

**Animal models**

Mice that constitutively overexpress human MMP-1 develop spontaneous air space enlargement, showing that MMP-1 can drive pulmonary destruction. Since that report, numerous transgenic mouse models have been developed in which emphysema-like changes develop. For example, targeted overexpression of IFN-$\gamma$, IL-13, or TNF-$\alpha$ causes inflammation and air space enlargement accompanied by the upregulation of numerous proteases. Similarly, macrophage colony stimulating factor (M-CSF) deficient mice, surfactant protein D deficient mice, and integrin $\alpha\beta_{6}$ deficient mice also develop air space enlargement. In all these models increased MMP activity has been demonstrated and, furthermore, mice deficient in MMP-12 are resistant to the pathological changes of cigarette smoke exposure. The absence of MMP inhibitors can also result in abnormal pulmonary matrix turnover as TIMP-3 deficient mice spontaneously develop air space enlargement at 2 weeks of age.

The functional importance of MMP activity in these models is confirmed by crossing emphysema developing mice with surfactant protein D deficient mice, and integrin $\alpha\beta_{6}$ deficient mice with MMP-12 deficient mice. Alveolar macrophages from patients with COPD express more MMP-1 and -9 than those from normal volunteers, and this is associated with increased secretion of active enzymes. No increase in MMP-12 expression or activity was found. MMP-9 secretion is further increased in response to inflammatory stimuli. The increased MMP-9 expression in macrophages is associated with increased MMP-9 activity in bronchoalveolar lavage (BAL) fluid. Alveolar macrophages secrete several elastolytic proteases and the contribution of MMPs to elastin degradation increases with time.

Although BAL fluid analysis provides a good indication of protease activity within the airways, it may not provide an indication of events within the interstitium where most of the tissue remodelling occurs. Also, studies using BAL fluid derived alveolar macrophages assume that they are the primary source of MMPs in emphysema, but stromal cells may make a greater contribution to ECM turnover. Immunohistochemistry does not have these limitations, and in an analysis of collagenase and gelatinase expression in COPD, MMP-1, -2, -8 and -9 were found to be upregulated. Neutrophils were identified as the primary source of MMP-8 and -9, while MMP-1 and -2 were expressed by macrophages and epithelial cells. Increased MMP-14 expression has also been demonstrated in emphysematous lungs by immunohistochemistry and by western blotting. In a study combining RT-PCR, ELISA, immunohistochemistry and a collagen degradation assay to analyse MMP-1,-9 and -12, increased MMP-1 expression was observed in patients with COPD. Type II pneumocytes were identified as a main source of MMP-1, suggesting that inflammatory cells may not be exclusively responsible for tissue destruction in emphysema. MMP-1 expression correlated with increased collagenase activity in homogenised lung samples. In contrast to the BAL fluid studies, MMP-9 expression did not differ between emphysema and control samples. Again, no MMP-12 expression was found in human disease, despite the critical role for MMP-12 in the mouse model of emphysema. However, another study did show increased MMP-12 expression in smokers with COPD compared with normal smokers. Increased MMP-1 expression in epithelial cells of the proposed orthologue, Mucol-A, has greatly reduced activity against type I collagen compared with human MMP-1, and in human disease MMP-1 may play a primary role, as outlined below. Secondly, in some models changes develop early in life so may result from developmental abnormalities as opposed to reflecting the exogenous insults that cause COPD in humans.

The guinea pig presents an alternative to the mouse in the study of cigarette smoke induced lung damage and MMP activity has also been implicated in this model. Smoke exposed guinea pigs have increased pulmonary collagenase levels as analysed by gene expression, immunoreactive protein, and activity. This upregulation of collagenase activity is associated with a reduction in total lung collagen. Furthermore, the pathological changes are reduced by a broad spectrum MMP inhibitor, demonstrating the therapeutic potential of targeting MMPs in COPD.

**Human studies**

The models described above indicate that MMP-9 and MMP-12 play key roles in destructive pulmonary pathology in mice and that collagenase activity is important in guinea pigs. However, studies in patients suggest that the spectrum of MMPs in human disease may differ significantly from these models. Clinical studies are often limited by demonstrating association as opposed to causation, but clinical investigation is essential to identify which proteases are critical in pulmonary disease in man.
SARCOIDOSIS
Sarcoidosis is a syndrome affecting multiple organs with diverse clinical presentations. Granuloma formation is common to all disease manifestations and results in extensive ECM remodelling. Collagenase activity can be detected in the BAL fluid of patients with sarcoidosis and, when present, is associated with a lower carbon monoxide transfer factor. Furthermore, the decline in lung function is more rapid in collagenase positive patients. MMP-8 appears to be responsible for this activity since MMP-8 levels and collagenase activity correlate. MMP-9 levels are also increased in the BAL fluid and induced sputum of patients with sarcoidosis, with no compensatory increase in the levels of the inhibitor TIMP-1. The cellular source of MMPs may primarily be multinucleate giant cells since they are highly immunoreactive for MMP-1 and -9. The pathological result of this unopposed protease activity is disruption of the basement membrane as focal damage is observed on staining for type IV collagen. Such data implicate MMP activity in initiating ECM breakdown and remodelling that can lead to the decline in lung function that occurs in advanced pulmonary sarcoidosis.

TUBERCULOSIS
Myobacterium tuberculosis is one of the most successful human pathogens of all time and remains a global health crisis. ECM destruction is fundamental to the success of M. tuberculosis since it allows cavitation and thereby creates an immunoprivileged site within which the organism can proliferate and then spread to new hosts. The reduced immune surveillance of the cavity is demonstrated by the ability of less virulent pathogens such as M. intracellulare, M. xenopi, and Aspergillus fumigatus to occupy a pre-existing pulmonary cavity. However, the ability to create a cavity in previously normal lung distinguishes M. tuberculosis from these opportunistic infections. If M. tuberculosis infects organs other than the lung it will usually reach a biological dead end, killing its host and failing to spread to a new one. Surprisingly, the mechanisms by which it causes lung destruction are poorly understood. As collagen and elastin must be degraded to allow cavity formation, MMPs are likely to be involved in the pathology of TB.

Animal studies
Guinea pigs present a relatively good model of human TB, with granuloma morphology that is similar to human disease but cavitary disease rarely develops. The water soluble fraction of M. smegmatis can increase collagenase secretion by guinea pig macrophages, but more extensive analysis of MMP activity in guinea pig TB has not been undertaken. Mice are a very useful model of immunity to M. tuberculosis, with many findings such as the key roles of CD4+ cells, TNF-α and IFN-γ first identified in the mouse later confirmed in man. However, the pulmonary pathology of TB infection in the mouse is very different from that in humans. Mice develop progressive pulmonary fibrosis, as occurs in advanced human TB, but do not cavitate. We hypothesise that this difference may result in part from the lack of a functional homologue of human MMP-1 in the mouse.

In mice, M. tuberculosis results in increased levels of MMP-2 and MMP-9 in infected tissues and infection of murine macrophages increases MMP-9 secretion. Broad spectrum MMP inhibition in a mouse model of TB led to more rapid disease progression and a deficiency in IL-1 and IL-2 secretion with a relative excess of IL-4, demonstrating a deviation in the immune response to a Th2 profile. In another murine study MMP inhibition was reported to lead to reduced bloodborne M. tuberculosis with smaller granulomas, less cell recruitment, and more collagen deposition.
This suggests that MMP activity may contribute to mycobacterial dissemination by facilitating erosion from the alveolus. However, the lack of specificity of BB-94, the MMP inhibitor used in these two studies, makes interpretation difficult. BB-94 also inhibits members of the ADAM family including ADAM-17 (TNF-α cleaving enzyme, TACE), so the deviated immune response may be due to inhibition of TNF-α release which is vital to an effective immune response to *M tuberculosis*.

**Human studies**

The first indication that MMPs may be involved in tissue destruction in TB came in 1996 when it was shown that mycobacterial lipoarabinomannan (LAM), a major antigenic cell wall component of *M tuberculosis*, increases MMP-1 and MMP-9 gene expression in the human THP-1 cell line.\(^{80}\) Furthermore, MMP-9 mRNA accumulation was shown in cells isolated by BAL from two patients with active pulmonary TB.\(^{80}\) Circulating MMP-9 levels correlate with disease severity of TB, with highest levels in those with the most extensive disease, while MMP-2 levels do not differ between groups.\(^{80}\) In an analysis of TB pleural effusions, higher levels of MMP-1, -2, -8 and -9 were found in patients with TB than in patients with congestive heart failure (unpublished data).\(^{82}\)\(^{83}\)

In TB meningitis our group has shown a matrix degrading phenotype in the cerebrospinal fluid where increased MMP-9 concentrations are unopposed by a compensatory increase in TIMP-1 levels.\(^{84}\) Extensive disease occurs in TB despite a relatively low bacterial load, suggesting that host immunity and intercellular networks may drive MMP secretion. Consistent with this, the immunohistochemistry of TB lymph node granulomas shows extensive MMP-9 staining with minimal TIMP-1 expression despite the presence of only small numbers of bacilli.\(^{85}\) However, the ECM of the lung differs from that of brain and lymph nodes, so the key MMPs in pulmonary TB and extrapulmonary disease may not be the same.

We have recently studied MMP expression in pulmonary TB. In a global analysis of MMP and TIMP gene expression in *M tuberculosis* infected human macrophages, MMP-1 and -7 were most potently upregulated.\(^{86}\) The induction of these specific MMPs may drive matrix destruction, as MMP-1 degrades type I collagen and MMP-7 is a potent elastase.\(^{87}\) MMP-9 gene expression and secretion was unchanged, showing that MMP regulation differs between human cell lines, undifferentiated monocytes, and macrophages. This suggests that MMP-9 expression may occur at specific phases of granuloma development. MMP-1 and -7 were expressed in caseating granulomas of patients with active culture proven TB but not in control patients. Airway epithelial cells were also strongly immunoreactive for MMP-1, showing that stromal cells may contribute to tissue destruction (fig 1).\(^ {87}\)

In culture, epithelial cell MMP-1 expression is driven by a monocyte dependent network. *M tuberculosis* therefore drives a matrix degrading phenotype both by direct infection of macrophages and by an intercellular network that increases MMP secretion by epithelial cells (fig 2).

**MMPs as Therapeutic Targets**

The data outlined above implicate excess MMP activity in the pathogenesis of COPD, ARDS, sarcoidosis, and TB. It therefore follows that modulating MMP activity may reduce immunopathology. The initial interest in therapeutic targeting of MMPs concentrated on cancer, although to date the results have been disappointing.\(^ {34}\) However, in pulmonary disease, MMP inhibition can prevent pathological changes of emphysema\(^ {82}\) and ARDS\(^ {70}\) in animal models. In human disease, global MMP inhibition may have deleterious effects as it may suppress the key immunoregulatory functions of MMPs. Mechanisms to target specific MMPs are therefore required. This may be achieved either by generating new chemical inhibitors with a narrower spectrum of activity than those available or by targeting the pathways that regulate MMP secretion such as the mitogen activated protein kinases. In order to realise the potential of MMP inhibition...
in human pulmonary disease, we must first dissect the balance between the immunological and pathological roles of critical MMPs. Next, the differences between animal models of lung disease and human disease must be further defined to ensure that animal studies of MMP inhibition reflect human disease more closely. If this can be achieved, suppression of excess MMP activity may reduce immunopathology in several pulmonary diseases.

CONCLUSIONS

MMPs are very likely to have a central role in destructive pulmonary diseases where excess proteolytic activity causes aberrant degradation of the lung ECM. Although MMPs play important roles in normal pulmonary immunity, in excess they can contribute to immunopathology that leads to morbidity and mortality. Further definition of the roles of individual MMPs in health and disease is required to allow targeted treatment that will protect the lung from excess MMP activity without compromising normal matrix remodelling and immunity.

ACKNOWLEDGEMENTS

The authors thank Dr Cecilia O’Kane and Dr Danny McAuley for critical reading of the manuscript.

Authors’ affiliations
PT G Elkington, J S Friedland, Department of Infectious Diseases, Imperial College Hammarsmith, London, UK
PE was a Wellcome Trust Clinical Research Training Fellow. JSF is supported by the Wellcome Trust and the Medical Research Council (UK) for MMP research.

The authors have no competing financial interests.

REFERENCES

Matrix metalloproteinases and tissue inhibitors of metalloproteinases (TIMPs) are involved in a variety of pulmonary diseases. These enzymes are responsible for the degradation of extracellular matrix proteins, which play crucial roles in immune responses, elastolysis, and fibrosis. Studies have shown that the balance between matrix metalloproteinases and TIMPs is disrupted in chronic obstructive pulmonary disease (COPD) and emphysema, leading to the formation of destructive processes such as emphysema and pulmonary fibrosis.

In a study by Araya et al. (1997), the authors observed intense inflammatory and profibrotic reactions in the early phase of acute lung injury, which improves survival after cecal ligation and puncture in rats. This suggests that the timely regulation of matrix metalloproteinases and TIMPs is essential for the resolution of acute lung injury.

Another study by Park et al. (2003) showed that the use of BB-94, a tissue inhibitor of metalloproteinase (TIMP)-1, in cryptogenic organizing pneumonia improved survival. This highlights the importance of TIMPs in the resolution of acute lung injury.

Research by Sterk et al. (2005) demonstrated that the expression of matrix metalloproteinase-9 is correlated with disease severity in tuberculosis patients. The role of metalloelastase in immune responses and tissue inhibitors of metalloproteinase-1 in M. tuberculosis but not in M. tuberculosis-induced BAL fluid in patients with sarcoidosis was studied by O'Keeffe et al. (2002). This suggests that matrix metalloproteinases contribute to the pathogenesis of sarcoidosis.

In a study by Quiding-Jarbrink et al. (2003), the authors observed increased expression of matrix metalloproteinase-9 and TIMP-2 in tuberculosis patients. This indicates that TIMPs play a role in the resolution of tuberculosis.

The role of matrix metalloproteinases and TIMPs in pulmonary diseases is further supported by a study by Perez-Ramos et al. (2002), who observed increased expression of TIMP-1 in idiopathic pulmonary fibrosis. This suggests that TIMPs have a protective role in the resolution of pulmonary fibrosis.

In conclusion, the expression and activity of matrix metalloproteinases and TIMPs are important in the pathogenesis and resolution of pulmonary diseases. Further research is needed to fully understand the role of these enzymes in these conditions.


---

Committee on Publication Ethics – Seminar 2006

9.30am–5pm Friday 10th March 2006, BMA House, London, UK

This year’s seminar takes an international perspective and addresses publication ethics and research in several European countries and beyond, with interactive workshops on common ethical and editorial dilemmas. The manipulation of impact factors, and whether unethical, will also be considered.

The seminar is for editors, authors, and all those interested in increasing the standard of publication ethics. The seminar will include:

- Professor Michael Farthing – the Panel for Research Integrity (UK)
- Publication ethics and research in other countries, including those in Northern Europe, Turkey, and China
- Publication ethics in animal research
- Making the COPE website work for you – real time demonstration on how to use the website
- New indexing services
- Interactive workshops – common ethical and editorial dilemmas for editors
- Opportunities to network with other editors and share your experiences and challenges

The seminar is free for COPE members and £30.00 + VAT for non-members. Numbers are limited and early booking is advisable. For registrations or more information please contact the COPE Secretary at cope@bmjgroup.com or call 020-7383-6602.

For more information on COPE see www.publicationethics.org.uk